1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
56.13%
Cash & equivalents changing by 56.13% while Drug Manufacturers - Specialty & Generic maintains stable levels. Benjamin Graham would examine if this divergence is justified.
-59.57%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
15.35%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
13.57%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
3.26%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-11.53%
1.25-1.5x Drug Manufacturers - Specialty & Generic median of -7.89%. Guy Spier is cautious about potential short-term asset bloat.
7.37%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-3.67%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
-0.04%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-1.57%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.37%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.52%
1.25-1.5x Drug Manufacturers - Specialty & Generic median of -0.40%. Guy Spier is cautious about intangible buildup outpacing the median.
-0.50%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
11363000100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-3.90%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.12%
Below half the Drug Manufacturers - Specialty & Generic median of -0.22%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
2.91%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
16.89%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-69.41%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
184.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
184.56%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
473.63%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-9.09%
Below half Drug Manufacturers - Specialty & Generic median of 0.30%. Joel Greenblatt sees more conservative short-term leverage than peers.
-1.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
-17.49%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential shortage of multi-year commitments.
51.82%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
700.28%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
9.66%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
7.79%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-1.21%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.41%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-0.72%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
2.50%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
2.91%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
-39.80%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-19.58%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-52.60%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
